Reactivation of latent hepatitis B infection during immunosuppressive therapy with guselkumab for plaque psoriasis: a case report-Reference-Cited by-同舟云学术

Reactivation of latent hepatitis B infection during immunosuppressive therapy with guselkumab for plaque psoriasis: a case report

Published:2023-12-27 Issue: Volume: Page:468-474
ISSN:
Container-title:Exploration of Drug Science
language:
Short-container-title:Explor Drug Sci

Author:

Franchi Elena¹^ORCID,Costanzo Arianna A. C.¹,Cursaro Carmela²^ORCID,Lonardo Amedeo²^ORCID,Lasagni Claudia³,Andreone Pietro⁴^ORCID

Affiliation:

1. Postgraduate school of Internal Medicine, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria di Modena, Ospedale Civile di Baggiovara, 41126 Modena, Italy

2. Department of Internal Medicine, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria di Modena, Ospedale Civile di Baggiovara, 41126 Modena, Italy

3. Department of Dermatology, Head and Neck Skin Cancer Service, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria di Modena, Ospedale Civile di Baggiovara, 41126 Modena, Italy

4. Department of Internal Medicine and Chief of postgraduate school of Allergy and Clinical Immunology, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria di Modena, Ospedale Civile di Baggiovara, 41126 Modena, Italy

Abstract

Reactivation of hepatitis B virus (HBV; RHBV) is a significant concern during immunosuppressive therapy, as it can lead to severe hepatitis and liver failure. The article reports a case of RHBV during treatment with guselkumab, an interleukin-23 inhibitor in a patient with inactive HBV infection and psoriasis. This report highlights the importance of screening for HBV prior to immunosuppressive therapy and initiating prophylactic therapy when necessary to prevent reactivation and its complications.

Publisher

Open Exploration Publishing

Subject

General Medicine,General Earth and Planetary Sciences,General Environmental Science,General Medicine,Ocean Engineering,General Medicine,General Medicine,General Medicine,General Medicine,General Earth and Planetary Sciences,General Environmental Science,General Medicine

Reference21 articles.

1. Global health sector strategy on viral hepatitis 2016-2021. Towards ending viral hepatitis [Internet]. Geneva: World Health Organization; [cited 2016 May 17]. Available from: https://www.who.int/publications/i/item/WHO-HIV-2016.06

2. Lee WM. Hepatitis B virus infection. N Engl J Med. 1997;337:1733–45.

3. Lee HW, Lee JS, Ahn SH. Hepatitis B virus cure: targets and future therapies. Int J Mol Sci. 2020;22:213.

4. Fanning GC, Zoulim F, Hou J, Bertoletti A. Therapeutic strategies for hepatitis B virus infection: towards a cure. Nat Rev Drug Discov. 2019;18:827–44. Erratum in: Nat Rev Drug Discov. 2020;19:291.

5. Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. Gastroenterology. 2017;152:1297–309.